Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.
Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.
Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.